Gain Therapeutics Shows Positive Results in Parkinson’s Trial

Gain Therapeutics' GT-02287 showed a reduction in GCase substrate in cerebrospinal fluid in a Phase 1b Parkinson's trial. The observation suggests increased GCase activity in the brain, potentially impacting disease progression.